Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Avaria Health & Beauty Corp.
WARNING LETTER
•Avaria Health & Beauty Corp.•April 30, 2024

Avaria Health & Beauty Corp. – FDA Warning Letter, Apr 30, 2024

Record Details

The FDA issued a Warning Letter to Avaria Health & Beauty Corp. following an inspection from April 22-30, 2024, at their Cambridge, Ontario, facility. The inspection revealed significant Current Good Manufacturing Practice (CGMP) violations, rendering their drug products adulterated under the FD&C Act.

Key violations include: 1. **Failure to identity test components (21 CFR 211.84(d)(1)):** The firm did not adequately test incoming components, specifically each shipment of each lot of (b)(4), for identity, including a (b)(4) limit test, despite its high risk for (b)(4) and (b)(4) contamination. The firm's response was deemed inadequate for lacking sufficient detail on future testing and not addressing distributed products within expiry. 2. **Inadequate production and process control procedures (21 CFR 211.100(a)):** The firm failed to validate manufacturing processes and qualify equipment for OTC drug products, with the Quality Assurance Manager stating it was not their practice. The response lacked a detailed plan or supporting documentation for validation. 3. **Quality control unit failure (21 CFR 211.22):** The quality unit did not provide adequate oversight, failing to ensure robust procedures, adherence to practices, complete batch reviews, and approval of investigations.

These are repeat violations from a previous Warning

Company
Avaria Health & Beauty Corp.
Inspection date
April 30, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · fb69d2c1-4290-4dfb-9f69-ccb7f978bcea

Violation Codes10
21 CFR 21021 CFR 21121 CFR 211.84(d)(1)21 CFR 211.100(a)21 CFR 211.2221 CFR 211.34FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Avaria Health & Beauty Corp.
  • WARNING_LETTER - 2023-08-08August 8, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Avaria Health & Beauty Corp.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.